From Thalidomide to Pomalyst: Better living through chemistry

Posted on April 2, 2013 by David Altman BCH Technology office

Posted in Innovation, People, Therapeutics

In times past, a pharmaceutical chemist’s main focus was to synthesize novel molecules to treat diseases. Today, an increasingly popular alternative is to re-engineer an existing drug—and continually improve it even after FDA approval. That’s how Robert D’Amato, MD, PhD, developed Pomalyst®, recently approved to treat multiple myeloma and the most potent analog to date of...